Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs

Department of Social Medicine, University of Bristol, Canynge Hall, Bristol, UK.
Expert Review of Vaccines (Impact Factor: 4.22). 08/2009; 8(7):851-61. DOI: 10.1586/erv.09.48
Source: PubMed

ABSTRACT Effective vaccines provide direct protection to immunized individuals, but may also provide benefits to unvaccinated individuals by reducing transmission and thereby lowering the risk of infection. Such herd immunity effects have been demonstrated following the introduction of meningococcal serogroup C conjugate (MCC) vaccines, with reductions in disease attack rates in unimmunized individuals and significantly lower serogroup C carriage attributable to the vaccine introduction. In the UK, targeting teenagers for immunization was crucial in maximizing indirect effects, as most meningococcal transmission occurs in this age group. Questions remain regarding the duration of herd protection and the most appropriate long-term immunization strategies. The magnitude of the herd effects following MCC vaccination was largely unanticipated, and has important consequences for the design and evaluation of new meningococcal vaccines.

Download full-text


Available from: Martin C J Maiden, Aug 01, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Consultant 2 Summary The GAVI supported vaccinations differ widely in there potential effect on women's health and maternal health. Vaccines with an impact on women's health include hep B and HPV. These two vaccines address infections, which have been shown to lead to severe morbidity and mortality in adults. Cervical cancer is a leading cause of death in women in many low and middle income countries and HPV 16/18 cause 70% of cervical cancers. Liver cancer, albeit less important than cervical cancer still causes substantial deaths in women. As such, both cancers also affect maternal health. In high income countries around 3% of cervical cancers are diagnosed during pregnancy. The diagnosis and therapy of cervical cancer in pregnancy puts stress on women, and termination of pregnancy is often needed to prevent negative consequences for the mother. Primary prevention through vaccination might have here an important impact. The impact of a hep B infection on morbidity and mortality in pregnancy is unclear as too few studies have been published. Still some effect of vaccination, although probably small at population level, can be assumed. Tetanus vaccination during childhood and pregnancy has most probable already reduced the burden of maternal tetanus substantially. Few cases, often due to abortion, are still described today.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Meningococcal serogroup C conjugate immunization was introduced in the Dutch national immunization schedule at the age of 14 months, together with a large catch-up campaign in 2002. After introduction of this MenC immunization, the incidence of MenC completely disappeared from the immunized population and a large reduction of disease was observed in the non-immunized population. Little information was present on the longevity of immunity following a single MenC immunization. In this PhD thesis the immunity of the Dutch population was assessed before and after introduction of the vaccine. The study reveals that a single immunization is beneficial over naturally induced immunity against MenC and reveals that the persistence of MenC-specific antibodies gradually increases in relation with the age at the time of immunization. Therefore, the main success of the MenC immunization programme is mainly due to the large herd effect that was introduced after the mass catch-up campaign. However, children that receive a single MenC immunization at the age of 14 months may be at risk when they enter the adolescent age and therefore an additional immunization may be necessary. Furthermore, studies on the transfer of maternal antibodies from mother to neonate were performed and the kinetics of antibody responses following primary or secondary MenC conjugate vaccination were studied.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The reservoir for Neisseria meningitidis (Nm) is the human oropharynx. Implementation of Nm serogroup C (NmC) glycoconjugate vaccines directly reduced NmC carriage. Prophylactic vaccines are now available to prevent disease caused by the five major Nm disease causing serogroups (ABCWY). Nm serogroup B (NmB) vaccines are composed of antigens that are conserved across Nm serogroups and therefore have the potential to impact all Nm carriage. To assess the effect of these vaccines on carriage, standardized approaches to identify and group Nm are required. Real-time PCR (rt-PCR) capsule grouping assays that were internally controlled to confirm Nm species were developed for eight serogroups associated with carriage (A, B, C, E, W, X, Y and Z). The grouping scheme was validated using diverse bacterial species associated with carriage and then used to evaluate a collection of diverse Nm carriage isolates (n=234). A scheme that also included porA and ctrA probes was able to speciate the isolates, while ctrA also provided insights on the integrity of the polysaccharide loci. Isolates were typed for the Nm vaccine antigen factor H binding protein (fHbp), and were found to represent the known diversity of this antigen. The porA rt-PCR yielded positive results with all 234 of the Nm carriage isolates. Genogrouping assays classified 76.5% (179/234) of these isolates to a group, categorized 53 as nongenogroupable (NGG) and two as mixed results. Thirty seven NGG isolates evidenced a disrupted capsular polysaccharide operon judged by a ctrA negative result. Only 28.6% (67/234) of the isolates were serogrouped by slide agglutination (SASG), highlighting the reduced capability of carriage strains to express capsular polysaccharide. These rt-PCR assays provide a comprehensive means to identify and genogroup N. meningitidis in carriage studies used to guide vaccination strategies and to assess the impact of novel fHbp containing vaccines on meningococcal carriage.
    PLoS ONE 07/2015; 10(7):e0132140. DOI:10.1371/journal.pone.0132140 · 3.53 Impact Factor
Show more